AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Down 54.8% in May

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totaling 137,078 shares, a drop of 54.8% from the April 30th total of 303,165 shares. Based on an average daily trading volume, of 1,558,811 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.9% of the company’s stock are short sold.

Institutional Investors Weigh In On AIM ImmunoTech

Institutional investors have recently modified their holdings of the business. Sabby Management LLC bought a new stake in shares of AIM ImmunoTech in the third quarter valued at about $79,000. DRW Securities LLC boosted its position in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after acquiring an additional 26,254 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in shares of AIM ImmunoTech in the second quarter valued at about $87,000. Institutional investors own 12.02% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Ascendiant Capital Markets decreased their target price on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday. Zacks Research cut shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $9.00.

AIM ImmunoTech Stock Performance

AIM stock traded up $0.49 during midday trading on Monday, reaching $0.90. 358,268,105 shares of the company were exchanged, compared to its average volume of 56,286,344. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01. The business has a 50-day moving average price of $0.51 and a two-hundred day moving average price of $0.95. AIM ImmunoTech has a one year low of $0.21 and a one year high of $20.35. The firm has a market capitalization of $13.08 million, a price-to-earnings ratio of -0.14 and a beta of 1.18.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.69) EPS for the quarter. The business had revenue of $0.02 million for the quarter. Equities research analysts forecast that AIM ImmunoTech will post -1.47 EPS for the current year.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.